COVID-19:富士フイルム、アビガンでインド製薬と提携:with Dr. Reddy’s and GRA COVID-19: Fujifilm form a partnership with Dr. Reddy’s /Global Response Aid: for the  drug Avigan. COVID-19:Fujifilm和Avigan与一家制药公司建立了合作关系:与Reddy博士和全球响应援助组织合作

COVID-19:富士フイルム、アビガンでインド製薬と提携:with Dr. Reddy’s and GRA
COVID-19: Fujifilm form a partnership with Dr. Reddy’s /Global Response Aid: for the  drug Avigan.
COVID-19:Fujifilm和Avigan与一家制药公司建立了合作关系:与Reddy博士和全球响应援助组织合作

COVID-19:

富士フイルム:

7月1日、COVID-19治療薬・アビガンに関し、インドの製薬会社等と、提携しました。

インド大手製薬「ドクター・レディーズ・ラボラトリーズ」等と、海外での開発権、販売権を独占的に付与する契約を締結したと発表した。

今回の契約:

中国、ロシア以外の地域で、ドクター・レディーズなどが、独占的な権限を持つ代わりに、販売に応じた対価を富士フイルム側に支払う。

新型コロナの治療薬としての普及のため、契約先の販売ルートも使って、供給網を早期に確立します。

共同通信

https://this.kiji.is/650959550778623073

Fujifilm partners with Dr. Reddy’s and Global Response Aid for deployment of a COVID-19 treatment drug outside of Japan

TOKYO, July 1, 2020

FUJIFILM Corporation partners with

Dr. Reddy’s Laboratories Ltd. , a global pharmaceutical company headquartered in India

and

Global Response Aid , a global provider of medical supplies and pharmaceuticals,

aimed at overseas deployment of a treatment drug for the novel coronavirus infectious disease, or COVID-19.

On June 30, a Tripartite Licensing Agreement was concluded between

  1. FUJIFILM Toyama Chemical Co., Ltd.,
  2. Dr. Reddy’s, and
  3. GRA,

concerning the development, manufacture and sales of Avigan® Tablets (generic name: favipiravir) (hereinafter “Avigan”), which is a potential drug for a treatment of COVID-19.

Under the Agreement, FUJIFILM Toyama Chemical

will grant Dr. Reddy’s and GRA the exclusive right to develop, manufacture*1 and sell Avigan overseas*2, and, receive a lump-sum license fee and royalties on sales.

Based on the Agreement, FUJIFILM Toyama Chemical

will provide Dr. Reddy’s and GRA an array of data on Avigan’s preclinical and clinical studies that

FUJIFILM Toyama Chemical

has accumulated thus far. Dr. Reddy’s and GRA, for their part, will make use of this data to swiftly implement clinical studies,

targeting COVID-19 patients in

  1. India,
  2. the Middle East, and
  3. other regions where infections have been spreading.

In addition, FUJIFILM Toyama Chemical

will grant Dr. Reddy’s right to use Avigan’s patents of formulation and manufacturing method.

Dr. Reddy’s

will herewith establish a setup for manufacturing drugs of the same quality as Avigan, and utilize GRA’s global sales network to supply the manufactured drugs swiftly and in a stable manner.

Dr. Reddy’s is a global pharmaceutical company which develops, manufactures, and sells generic drugs.

It has been expanding business not only in India but also in Europe, the US and several other markets across the world and is accelerating its global business development.

GRA, a company based in Dubai,

offers medical supplies, drugs, and medical services worldwide in cooperation with drug and medical device manufacturers.

Fujifilm [Japan]

https://www.fujifilm.com/jp/en/news/hq/5109

Dr. Reddy’s partners with FUJIFILM and Global Response Aid for Avigan® (favipiravir), a potential treatment of COVID-19

https://www.drreddys.com/media/904732/press-release_dr-reddys-avigan.pdf

Agility launches Dubai-based Global Response Aid in Covid-19 fight

https://www.google.co.jp/amp/s/amp.arabianbusiness.com/amp/article_listing/aben/transport/446422-agility-launches-dubai-based-global-response-aid-in-covid-19-fight